Physician profile
Michael Guma
NPI 1376655407
$19,038.88
in general payments reported to CMS, 2019-2025
36 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,205 · 2020: $1,475 · 2021: $9,220 · 2022: $2,012 · 2023: $1,309 · 2024: $761 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,947 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,947.03 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $6,924.48 | 2021-2023 | Lupkynis |
| Amgen INC. | $1,694.20 | 2019-2025 | Tavneos, Krystexxa, Uplizna |
| Janssen Biotech, INC. | $1,545.73 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $1,266.54 | 2019-2022 | |
| Abbvie INC. | $1,010.73 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $958.39 | 2019-2025 | Sotyktu, Orencia |
| Lilly USA, LLC | $732.34 | 2019-2024 | Taltz |
| Novartis Pharmaceuticals Corporation | $718.63 | 2019-2023 | |
| Pfizer INC. | $693.52 | 2019-2023 | |
| Horizon Therapeutics Plc | $561.48 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $455.14 | 2019-2024 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.43 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $339.16 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $205.20 | 2021-2023 | |
| Ucb, INC. | $182.26 | 2019-2023 | Cimzia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $174.41 | 2019-2023 | Euflexxa |
| Medexus Pharma, INC. | $154.76 | 2019-2020 | |
| Depuy Synthes Sales INC. | $137.52 | 2019-2022 | |
| Genentech USA, INC. | $129.17 | 2019-2020 | |
| Sobi, INC | $105.92 | 2019-2022 | |
| Octapharma USA, INC. | $105.48 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $100.00 | 2023 | |
| Sanofi-Aventis U.S. LLC | $65.49 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $57.01 | 2021-2023 | Acthar |
| Fidia Pharma USA INC. | $49.55 | 2019-2021 | |
| Daiichi Sankyo INC. | $43.30 | 2020 | |
| Antares Pharma, INC. | $43.13 | 2019-2020 | |
| Radius Health, INC. | $40.24 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $29.86 | 2023 | |
| Zimmer Biomet Holdings, INC. | $25.78 | 2019 | |
| Boston Scientific Corporation | $25.15 | 2019 | |
| Hikma Pharmaceuticals USA | $14.32 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.31 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $13.06 | 2022 | |
| Merck Sharp & Dohme LLC | $11.12 | 2019 | |
| Organon LLC | $10.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Guma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.